First American Gains Therapeutic Benefit From Rexin-G

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Epeius Biotechnologies Corporation, today announced that the first American with advanced pancreatic cancer has responded favorably to Rexin-G, the leading tumor- targeted injectable gene therapy vector for metastatic cancer.